Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
NCT06414044 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2026-01-21
Summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of atogepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Conditions
- Migraine
- Migraine With Aura
- Migraine Without Aura
- Chronic Migraine
Interventions
- DRUG
-
Atogepant 60 mg
Patients using atogepant 60 mg tablet daily as migraine prevention
Sponsors & Collaborators
-
Fondazione Policlinico Universitario Campus Bio-Medico
collaborator OTHER -
IRCCS National Neurological Institute "C. Mondino" Foundation
collaborator OTHER -
Società Italiana per lo Studio delle Cefalee
collaborator OTHER -
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
collaborator OTHER -
Università degli Studi dell'Aquila
collaborator OTHER -
University of Roma La Sapienza
collaborator OTHER -
Azienda Ospedaliero Universitaria Policlinico Modena
collaborator OTHER -
Euganea Health Unit, Padua, Italy
collaborator UNKNOWN -
Azienda Ospedaliero-Universitaria di Parma
collaborator OTHER -
Azienda Ospedaliera S. Maria della Misericordia
collaborator OTHER -
A.O.U. Città della Salute e della Scienza
collaborator OTHER -
Cliniche Humanitas Gavazzeni
collaborator OTHER -
University of Campania Luigi Vanvitelli
collaborator OTHER -
Ospedale Santo Stefano
collaborator OTHER -
Azienda Policlinico Umberto I
collaborator OTHER -
Auxologico San Luca
collaborator OTHER -
Asst Degli Spedali Civili Di Brescia
collaborator OTHER -
University of Florence
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-09
- Primary Completion
- 2025-11-30
- Completion
- 2026-04-30
Countries
- Italy
Study Locations
More Related Trials
-
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122 ·Status: RECRUITING
-
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136 ·Status: COMPLETED ·Phase: PHASE3
-
Atogepant in Real Life in Italy (GIANT)
NCT06136442 ·Status: NOT_YET_RECRUITING
-
Effectiveness and Tolerability of Eptinezumab
NCT06409845 ·Status: RECRUITING
-
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
NCT02848326 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.
NCT04740827 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine
NCT04829747 ·Status: COMPLETED ·Phase: PHASE3
-
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT03777059 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
NCT05861427 ·Status: COMPLETED ·Phase: PHASE3
-
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
NCT06409832 ·Status: RECRUITING
-
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
NCT06603558 ·Status: RECRUITING
-
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
NCT05707949 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Ditan Acute tReatments: Effectiveness and Tolerability (DART)
NCT05903040 ·Status: COMPLETED
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·Status: RECRUITING ·Phase: PHASE3
-
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750 ·Status: RECRUITING
-
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
NCT04818515 ·Status: COMPLETED ·Phase: PHASE1
-
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
NCT06248671 ·Status: RECRUITING ·Phase: PHASE2
-
Real-life Study of the Efficacy of Management of Migraine Patients After Failure of 2 Prophylactic Treatments
NCT05947123 ·Status: COMPLETED
-
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
NCT05653986 ·Status: COMPLETED
-
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05264129 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 ·Status: RECRUITING ·Phase: PHASE4